Wolfgang Fischbach1, Peter Malfertheiner. 1. Department II, Gastroenterology and Oncology, Klinikum Aschaffenburg - Alzenau GmbH, Academic Teaching Hospital of the University of Würzburg; Clinic for Gastroenterology, Hepatology, and Infectious Diseases, University Clinic Magdeburg.
Abstract
BACKGROUND: Infection with Helicobacter pylori (H. pylori) is a major pathogenic factor for gastroduodenal ulcer disease and gastric carcinoma, as well as for other types of gastric and extragastric disease. As a result of changing epidemiologic conditions (e.g., immigration), changing resistance patterns with therapeutic implications, and new knowledge relating to the indications for pathogen eradication, the medical management of H. pylori is a dynamic process in need of periodic reassessment. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed and the Cochrane Database, with particular attention to three international consensus reports and the updated German S2k guideline. RESULTS: H. pylori is now dealt with as an infection, whether or not the infected individual has symptoms or suffers from and H.-pylori-induced illness. H.-pylori-associated dyspepsia and functional dyspepsia are distinct entities that can only be diagnosed when competing elements in the differential diagnosis have been ruled out. H. pylori can be detected with noninvasive methods (13C-urea breathing test, stool antigen detection) and with invasive methods (histology, culture, rapid urease test). An important consideration for treatment is that primary clarithromycin resistance is common in many groups of patients; in Germany, its prevalence is now 10.9%. Primary treatment can be with either standard triple therapy (clarithromycin and amoxicillin or metronidazole) or bismuth-containing quadruple therapy. Treatment for 10 to 14 days is more likely to eradicate the pathogen than treatment for 7 days. When H. pylori infection is initially diagnosed in a patient over age 50, gastritis risk stratification should be performed by means of endoscopic biopsy and histologic examination. CONCLUSION: The new, clinically relevant developments that are presented and commented upon in this review now enable evidence-based management of H. pylori infection.
BACKGROUND:Infection with Helicobacter pylori (H. pylori) is a major pathogenic factor for gastroduodenal ulcer disease and gastric carcinoma, as well as for other types of gastric and extragastric disease. As a result of changing epidemiologic conditions (e.g., immigration), changing resistance patterns with therapeutic implications, and new knowledge relating to the indications for pathogen eradication, the medical management of H. pylori is a dynamic process in need of periodic reassessment. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed and the Cochrane Database, with particular attention to three international consensus reports and the updated German S2k guideline. RESULTS:H. pylori is now dealt with as an infection, whether or not the infected individual has symptoms or suffers from and H.-pylori-induced illness. H.-pylori-associated dyspepsia and functional dyspepsia are distinct entities that can only be diagnosed when competing elements in the differential diagnosis have been ruled out. H. pylori can be detected with noninvasive methods (13C-urea breathing test, stool antigen detection) and with invasive methods (histology, culture, rapid urease test). An important consideration for treatment is that primary clarithromycin resistance is common in many groups of patients; in Germany, its prevalence is now 10.9%. Primary treatment can be with either standard triple therapy (clarithromycin and amoxicillin or metronidazole) or bismuth-containing quadruple therapy. Treatment for 10 to 14 days is more likely to eradicate the pathogen than treatment for 7 days. When H. pyloriinfection is initially diagnosed in a patient over age 50, gastritis risk stratification should be performed by means of endoscopic biopsy and histologic examination. CONCLUSION: The new, clinically relevant developments that are presented and commented upon in this review now enable evidence-based management of H. pyloriinfection.
Authors: W Fischbach; P Malfertheiner; J C Hoffmann; W Bolten; J Bornschein; O Götze; W Höhne; M Kist; S Koletzko; J Labenz; P Layer; St Miehlke; A Morgner; U Peitz; J C Preiss; C Prinz; U Rosien; W E Schmidt; A Schwarzer; S Suerbaum; A Timmer; G Treiber; M Vieth Journal: Z Gastroenterol Date: 2009-01-20 Impact factor: 2.000
Authors: Carlo A Fallone; Naoki Chiba; Sander Veldhuyzen van Zanten; Lori Fischbach; Javier P Gisbert; Richard H Hunt; Nicola L Jones; Craig Render; Grigorios I Leontiadis; Paul Moayyedi; John K Marshall Journal: Gastroenterology Date: 2016-04-19 Impact factor: 22.682
Authors: Ji Yeon Seo; Dong Ho Lee; Yuri Cho; Dong Hyeon Lee; Hong Sang Oh; Hyun Jin Jo; Cheol Min Shin; Sang Hyub Lee; Young Soo Park; Jin Hyeok Hwang; Jin Wook Kim; Sook Hyang Jeong; Nayoung Kim; Hyun Chae Jung; In Sung Song Journal: Hepatogastroenterology Date: 2012-11-20
Authors: Francis K L Chan; Jessica Y L Ching; Bing Yee Suen; Yee Kit Tse; Justin C Y Wu; Joseph J Y Sung Journal: Gastroenterology Date: 2013-01-16 Impact factor: 22.682
Authors: Richard F Knoop; Pauline C Gaertner; Golo Petzold; Ahmad Amanzada; Volker Ellenrieder; Albrecht Neesse; Sebastian C B Bremer; Steffen Kunsch Journal: Biomed Res Int Date: 2022-04-25 Impact factor: 3.246